NEOG

Neogen Corp

Add to Watchlist

Advanced Chart

5.000

+0.23(4.822%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.010

Open

4.880

VWAP

4.93

Vol

4.61M

Mkt Cap

1.09B

Low

4.780

Amount

22.74M

EV/EBITDA(TTM)

15.29

Total Shares

216.61M

1.80B

EV/OCF(TTM)

30.92

P/S(TTM)

1.16

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

199.40M

-9.77%

0.075

-25%

208.60M

-9.8%

0.060

-45.45%

202.67M

-6.59%

0.040

-42.86%

Estimates Revision

The market is revising Downward the revenue expectations for Neogen Corporation (NEOG) for FY2026, with the revenue forecasts being adjusted by -9.3% over the past three months. During the same period, the stock price has changed by -15.68%.

Revenue Estimates for FY2026

Revise Downward

-9.3%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-46.74%

In Past 3 Month

Stock Price

Go Down

-15.68%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast NEOG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEOG is 7.50 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 5.000

Low

5.00

Averages

7.50

High

10.00

Current: 5.000

Low

5.00

Averages

7.50

High

10.00

William Blair

Outperform -> Market Perform

downgrade

2025-07-29

Reason

William Blair

Price Target

2025-07-29

downgrade

Outperform -> Market Perform

Reason

William Blair downgraded Neogen to Market Perform from Outperform. The firm had remained bullish because of what it had seen as sales and profitability growth potential, but management pointed to a worsening macro environment that resulted in fiscal 2026 revenue guidance that implies flat to declining revenues. In this context, the firm does not see \"a pathway to improving markets, leaving us with tepid fiscal 2026 guidance,\" the analyst tells investors.

Guggenheim

Buy

downgrade

$13 -> $10

2025-06-30

Reason

Guggenheim

Price Target

$13 -> $10

2025-06-30

downgrade

Buy

Reason

Guggenheim lowered the firm's price target on Neogen to $10 from $13 and keeps a Buy rating on the shares. The firm's updated model includes a pro forma outlook of Neogen assuming current divestiture plans are finalized, as well as management's recent commentary on higher-than-anticipated inventory write-offs, which extends through 2026, the analyst tells investors in a research note.

Piper Sandler

David Westenberg

Hold

Maintains

$6.4 → $5

2025-04-22

Reason

Piper Sandler

David Westenberg

Price Target

$6.4 → $5

2025-04-22

Maintains

Hold

Reason

Piper Sandler analyst David Westenberg lowered the firm's price target on Neogen to $5 from $6.40 and keeps a Neutral rating on the shares. The firm cites a slower ramp in operating margins.

Piper Sandler

David Westenberg

Hold

Maintains

$13 → $6.5

2025-04-14

Reason

Piper Sandler

David Westenberg

Price Target

$13 → $6.5

2025-04-14

Maintains

Hold

Reason

Piper Sandler lowered the firm's price target on Neogen to $6.40 from $13 and keeps a Neutral rating on the shares following quarterly results. The firm cites updated estimates and updated multiple.

Guggenheim

Subbu Nambi

Strong Buy

Maintains

$15 → $13

2025-04-10

Reason

Guggenheim

Subbu Nambi

Price Target

$15 → $13

2025-04-10

Maintains

Strong Buy

Reason

Guggenheim lowered the firm's price target on Neogen to $13 from $15 and keeps a Buy rating on the shares. While a post-integration Neogen "seems to be in view," a CEO change and uncertain macro backdrop could extend near-term growth choppiness, the analyst tells investors.

Piper Sandler

David Westenberg

Hold

Reiterates

$17 → $13

2025-01-21

Reason

Piper Sandler

David Westenberg

Price Target

$17 → $13

2025-01-21

Reiterates

Hold

Reason

Piper Sandler analyst David Westenberg lowered the firm's price target on Neogen to $13 from $16.50 and keeps a Neutral rating on the shares following the company's earnings report. The firm notes that its change in price target primarily reflects its updated estimates and updated multiple.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Neogen Corp (NEOG.O) is 19.10, compared to its 5-year average forward P/E of 43.66. For a more detailed relative valuation and DCF analysis to assess Neogen Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

43.66

Current PE

19.10

Overvalued PE

63.55

Undervalued PE

23.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

23.20

Current EV/EBITDA

10.98

Overvalued EV/EBITDA

34.48

Undervalued EV/EBITDA

11.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

5.25

Current PS

1.24

Overvalued PS

7.87

Undervalued PS

2.62

Financials

Annual

Quarterly

FY2025Q4

YoY :

-4.79%

225.46M

Total Revenue

FY2025Q4

YoY :

-201.64%

-13.25M

Operating Profit

FY2025Q4

YoY :

+11205.56%

-612.20M

Net Income after Tax

FY2025Q4

YoY :

+9300.00%

-2.82

EPS - Diluted

FY2025Q4

YoY :

-83.71%

406.00K

Free Cash Flow

FY2025Q4

YoY :

-14.07%

41.18

Gross Profit Margin - %

FY2025Q4

YoY :

-37.14%

-5.18

FCF Margin - %

FY2025Q4

YoY :

+11757.21%

-271.53

Net Margin - %

FY2025Q4

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

771.9K

USD

Months

6-9

418.5K

USD

Months

0-12

200.1K

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 999.08% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

11.9M

Volume

Months

6-9

1.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

771.9K

USD

Months

6-9

418.5K

USD

Months

0-12

200.1K

USD

Months

NEOG News & Events

Events Timeline

2025-07-29 (ET)

2025-07-29

07:29:12

Neogen sees FY26 revenue $820M-$840M, consensus $803M

2025-07-29

07:27:48

Neogen reports Q4 adjusted EPS 5c, consensus 9c

2025-07-24 (ET)

2025-07-24

09:23:07

Neogen appoints Mike Nassif as CEO

News

7.0

08:34 AMGlobenewswire

Investors who lost money on Neogen Corporation (NEOG) should contact The Gross Law Firm about pending Class Action - NEOG

7.0

08-06Globenewswire

NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation - NEOG

7.0

08-06Globenewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Neogen Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEOG